What happened On October 16, 2026, AJMC published an item framed as an FAQ on how payers can ease drug cost burdens for patients. The piece said physician Siva Mohan, MD, explained how drug costs drive silent nonadherence, prior authorization burden, and biosimilar hesitancy, and what payers can do about it. The source also references PBM reform and supportive care needs in connection with Nicolas Ferreyros.
Why it matters Even in this very limited readout, the signal is clear: payer scrutiny is no longer just about unit price. AJMC highlighted nonadherence that stays hidden, administrative friction from prior authorization, and resistance around biosimilar uptake. Those pressure points hit the parts of the system where nominal savings can be offset by poorer execution. For plans and PBMs, that suggests the next phase of cost management will be judged less by headline restriction tools alone and more by whether those tools reduce total friction for patients and physicians. For employer-side PBM benchmarking, see RxPBM.ai.
One likely read is that biosimilar strategy remains vulnerable if payers cannot translate formulary intent into physician and patient confidence. The mention of supportive care needs also points toward a broader access conversation. Not just a rebate conversation. Investors and industry teams should watch whether this line of discussion shows up in more concrete benefit design changes, utilization management adjustments, or PBM reform proposals. For broader drug pricing context, see RxInfo.ai.
